Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10780300			
Filing Date		2004-02-17			
First Named Inventor	Edwa	ard K. O'neil			
Art Unit		2641			
Examiner Name					
Attorney Docket Numb	er	BEAS-01448US1			

	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Issue Date Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	5836014		1998-1	1998-11-10 Faiman						
	2	6732237	B1	2004-0	2004-05-04 Jacobs et al.						
	3	6804686	B1	2004-1	2004-10-12 Stone et al.						
	4	6028997	A1	2000-0	2-22	Leymann et al	L				
If you wish	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Cite   Publication Number   Kind   Publication   Name of Patentee of Applicant   R				Releva	Columns,Lir nt Passages s Appear						
	1										
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Adi	d button	Add		_
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or V	Pages,Colum where Releva Passages or Figures Appe	ant Relevant	T+

#### 

	1										
If you wis	h to a	dd additional Foreign Pa	stent Document	citation	information pl	lease click the Add bu	tton Add	Н			
	NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposism, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.										
	BLAKE, Rule-Driven Coordination Agents: "A Self-Configurable Agent Architecture for Distributed Control", IEEE March 2001, pages 271-277.										
	2 DAHALIN et al., "Workflow Interoperability Using Extensible Markup Language (XML), IEEE, July 2002, pages, 513-516										
	3 KUNSETTY, 'Workflow Modeling and Simulation Using an Extensible Object-Oriented Knowledge Based Management System' Citeseer, 1996 pages 1-60										

If you wish to add additional non-patent literature document citation information please click the Add button Add

## EYAMINER SIGNATURE

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

VAN DER AAIST et al., "Verification of XRL: An XML-Based Workflow Linaguage, IEEE, July 2001, pages 427-432

<sup>1</sup> See Knd Codes of USPTO Patent Documents at www.USPTO.0CV or MPEP 901.04. <sup>2</sup> Enter office that resued the document, by the two-letter code (WIPO Standard ST 3). <sup>3</sup> For Japanese patent documents, the indication of the year of the region of the region

Examiner Signature

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10780300			
Filing Date		2004-02-17			
First Named Inventor	Edwa	ard K. O'neil			
Art Unit		2641			
Examiner Name					
Attorney Docket Number		BEAS-01448US1			

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.5	97 and 1.98	to make the	appropriate	selection(	s):
---------------	---------	-------------	-------------	-------------	------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 137(a)(1).

#### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no terior information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3(f)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paul A. Durdik/	Date (YYYY-MM-DD)	2006-07-31
Name/Drint	Don't A. Duredile	Registration Number	37810

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.